Clinical trial of fusidic acid for lepromatous leprosy.
AUTOR(ES)
Franzblau, S G
RESUMO
Fusidic acid was assessed for antileprosy activity in nine lepromatous leprosy patients. Patients received fusidic acid at either 500 mg/day for 12 weeks or 750 mg/day for 4 weeks followed by 500 mg/day for 8 weeks. All patients showed time-dependent clinical improvement and decreases in bacillary morphological index, radiorespirometric activity and PCR signal, and in serum phenolic glycolipid I. Fusidic acid appears to be a weakly bactericidal antileprosy agent which may have a role in the multidrug treatment of leprosy pending an evaluation of lepra-reaction-suppressive activity.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=284609Documentos Relacionados
- Clinical trial of sparfloxacin for lepromatous leprosy.
- Clinical trial of clarithromycin for lepromatous leprosy.
- Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy.
- Regimens to treat lepromatous leprosy.
- CD2 expression and function in lepromatous leprosy.
